Sunday, 4 December, 2022
HomeWorldIndonesia approves China’s Sinovac Covid vaccine for emergency use

Indonesia approves China’s Sinovac Covid vaccine for emergency use

The vaccine was found to be about 65% effective against Covid in late stage-trials in the city of Bandung. The emergency use approval is the first for Sinovac’s shot outside of China.

Text Size:

Jakarta: Indonesia approved China’s Sinovac Biotech Ltd. shots for emergency use, paving the way for Southeast Asia’s largest economy to start its inoculation program.

The Sinovac vaccine was found to be about 65% effective against Covid-19 in late stage-trials in the city of Bandung, Penny Lukito, head of the food and drug regulator said in a press briefing Monday. The regulator also considered data from clinical trials in Brazil and Turkey in making the decision, she said.

The vaccine is “largely safe,” Lukito said. “It brings hope of reducing the Covid cases.”

The emergency use authorization is the first for Sinovac’s vaccine outside of China. In Brazil, late stage-trials showed an efficacy rate of 78%. The vaccine was effective in preventing mild cases of the virus and 100% effective against severe and moderate infections, according to the Brazil government.

Indonesia is struggling to rein in the worst coronavirus outbreak in Southeast Asia, with its positivity rate exceeding 31% on Monday in a sign of insufficient testing. The World Health Organization recommended the rate to be kept below 5%.

President Joko Widodo is set to receive the first shot on Jan. 13, along with social media influencers and religious leaders. Indonesia needs to boost confidence in the vaccine among its 270 million population to curb the outbreak that has so far infected over 770,000 people.

Sinovac has shipped 3 million doses of Covid-19 vaccines to Indonesia. The country plans to inoculate 181.5 million people by March 2022. –Bloomberg

Also read: Brazil trial shows Sinovac vaccine above 50% effective, but researchers delay full results


Subscribe to our channels on YouTube & Telegram

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

Most Popular